On Sunday, 3 January, the Drugs Controller General of India (DCGI) granted permission to Bharat Biotech’s indigenous COVID vaccine ‘Covaxin’ and Oxford-AstraZeneca’s Covishield vaccine for restricted use in emergency situation. "After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of Serum and Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to Cadila Healthcare for conduct of the Phase III clinical trial,” DCGI said in a press briefing. It further said that the vaccine of Serum Institute and Bharat Biotech have to be administered in two doses. Further, all the vaccines have to be stored at a temperature of 2-8 degree celsius.
On Sunday, 3 January, the Drugs Controller General of India (DCGI) granted permission to Bharat Biotech’s indigenous COVID vaccine ‘Covaxin’ and Oxford-AstraZeneca’s Covishield vaccine for restricted use in emergency situation. "After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of Serum and Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to Cadila Healthcare for conduct of the Phase III clinical trial,” DCGI said in a press briefing. It further said that the vaccine of Serum Institute and Bharat Biotech have to be administered in two doses. Further, all the vaccines have to be stored at a temperature of 2-8 degree celsius.
417.jpeg)
10.jpeg)
40.jpeg)
100.jpeg)
416.jpeg)
5.jpeg)
4.jpeg)
6.jpeg)
5.jpeg)
